The occurrence of Epstein-Barr virus (EBV) specific DNase antibodies was measured in the sera of 400 patients. Three hundred sera were positive (>20) for early antigen diffuse component (EA-D) antibodies, as measured by indirect immunofluorescence (IF). One hundred sera were EA-D antibody-negative but had IF IgG titers (>40) to the viral capsid antigen (VCA). Twenty-nine of the anti-EA-D-positive sera, and 14 of the anti-EA-D-negative sera showed specific inhibition of EBV DNase. The mean age of positive male patients (39 years) for DNase antibodies was significantly higher (p < 0.05) than the mean age of positive females (27 years). Thirteen of the 40 patients (29.5%) with acquired immunodeficiency syndrome (AIDS) had EBV DNase-neutralizing antibodies. No correlation between the level of anti-DNase antibodies and the antibody titer to EA-D or VCA was observed. These results support the notion that the EBV DNase antibody assay measures an independent index reflecting factual EBV disease.

Keywords:
Epstein-Barr virus, Dnase, AIDS, Antibody prevalence
This content is only available via PDF.
© 1989 S. Karger AG, Basel
1989
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.